Evidence map›Paper›PMID 34280201›Full record

ArticlePLoS neglected tropical diseases2021

Emergent canine visceral leishmaniasis in Argentina: Comparative diagnostics and relevance to proliferation of human disease.

Kyoko Fujisawa, Charlotte Silcott-Niles, Poppy Simonson, Daniela Lamattina, Cristian A Humeres, Tapan Bhattacharyya, Pascal Mertens, Caroline Thunissen, Victoria O'Rourke, Magdalena Pańczuk and 3 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Kyoko FujisawaFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-2515-9870
Charlotte Silcott-NilesFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Poppy SimonsonFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-4527-2029
Daniela LamattinaInstituto Nacional de Medicina Tropical (INMeT), ANLIS, Ministerio de Salud de la Nación, Puerto Iguazú, Misiones, Argentina.ORCID 0000-0002-5926-8234
Cristian A HumeresInstituto Nacional de Medicina Tropical (INMeT), ANLIS, Ministerio de Salud de la Nación, Puerto Iguazú, Misiones, Argentina.
Tapan BhattacharyyaFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-3385-2536
Pascal MertensCoris BioConcept, Gembloux, Belgium.ORCID 0000-0002-1458-8306
Caroline ThunissenCoris BioConcept, Gembloux, Belgium.
Victoria O'RourkeFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Magdalena PańczukFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
James A WhitworthFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0002-0234-8065
Oscar Daniel SalomónInstituto Nacional de Medicina Tropical (INMeT), ANLIS, Ministerio de Salud de la Nación, Puerto Iguazú, Misiones, Argentina.ORCID 0000-0002-6206-3862
Michael A MilesFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0002-5834-8734
London School of Hygiene & Tropical Medicine · GBConsejo Nacional de Investigaciones Científicas y Técnicas · ARCoris BioConcept (Belgium) · BE

Funding

Wellcome Trust 107779/Z/15/Z
6 · The paper itself

Abstract

backgroundVisceral leishmaniasis (VL) is a zoonotic protozoal vector-borne disease that is a major public health challenge. In Argentina, canine (CVL) and human visceral leishmaniasis (HVL) have recently emerged. There is a lack of standardised diagnostic tests for CVL, which hinders control of CVL and HVL. METHODOLOGY/PRINCIPAL

findingsSampling was carried out in Puerto Iguazú, Argentina, comprising 190 asymptomatic, oligosymptomatic and polysymptomatic dogs. The following diagnostics were applied: microscopy of lymph node aspirate (LNA); three immunochromatographic rapid diagnostic tests (RDTs), prototype rK28-ICT, rK39-ICT (both Coris BioConcept), commercial rK39 (InBios); ELISA for IgG, IgG1 and IgG2, against rK28, rK39 or crude lysate antigen. DNA detection and analysis, with 30 dogs, was of the ITS1 region using skin samples, and loop-mediated isothermal amplification (LAMP; Eiken Loopamp) of buffy coat, skin scrape or LNA. 15.4% of dogs were positive by LNA microscopy. The rK28 RDT had higher seropositivity rate (61%) than either a prototype rK39 RDT (31.4%) or commercial rK39 RDT (18.8%), without cross-reactivity with six other pathogens. IgG anti-rK39 ELISA antibody titres, but not IgG2, were positively correlated with number of clinical signs. LAMP with LNA had a higher positivity rate than PCR; buffy coat sampling was more sensitive than skin scrape. ITS1 confirmed Leishmania (Leishmania) infantum as the agent of CVL. Leishmania (Viannia) spp. was detected in skin samples from two dogs, compatible with Leishmania (Viannia) braziliensis. CONCLUSIONS/SIGNIFICANCE: Seroprevalence confirmed rapid increase in CVL in Puerto Iguazú. The rK28 RDT test potentially has great value for improved point-of-care diagnosis. Given cost reduction and accessibility, commercial LAMP may be applicable to buffy coat. RDT biomarkers of CVL clinical status are required to combat spread of CVL and HVL. The presence of Viannia, perhaps as an agent of human mucocutaneous leishmaniasis (MCL), highlights the need for vigilance and surveillance.

Indexed as

AnimalsArgentinaDiagnostic Tests, RoutineDog DiseasesDogsEnzyme-Linked Immunosorbent AssayHumansLeishmania infantumLeishmaniasis, VisceralMicroscopyMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesPolymerase Chain ReactionSensitivity and Specificity

Identifiers

PMID34280201
PMCPMC8289008
OpenAlexW3183295349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.